Key result
Single bolus t-PA matches infusion dosing for 60-minute infarct-related vessel patency and microvascular reperfusion.
Why the study?
Does single bolus administration of t-PA provide equivalent efficacy to infusion dosing for infarct related vessel patency and microvascular perfusion in a canine model of coronary occlusion?
Population
16 beagle dogs of either sex, weight 9.2-20.3 kg, with coronary arterial thrombi induced by a copper coil in…
Comparison
t-PA (0.6 x 10 IU.kg-1) by intravenous bolus… vs t-PA infused intravenously at 0.6 x 10…
Design
Preclinical, randomly assigned
Follow-up
2 h reperfusion period
Authors
Loading...
Supports bolus t-PA testing in human trials; leaves open translation to clinical STEMI outcomes.
RCT (n=16)
Randomized
Does single bolus administration of t-PA provide equivalent efficacy to infusion dosing for infarct related vessel patency and microvascular perfusion in a canine model of coronary occlusion?
Absolute Event Rate: 88% vs 88%
In a canine model of coronary occlusion, a single bolus of t-PA demonstrated equivalent efficacy to an infusion in achieving infarct-related vessel patency and microvascular reperfusion.
Longridge et al. (1991) conducted an RCT in Coronary arterial thrombotic occlusion (n=16). Recombinant tissue plasminogen activator (t-PA) single bolus vs. t-PA infused intravenously at 0.6 x 10(6) IU.kg-1.h-1 was evaluated on 60 minute infarct related vessel patency (IRVP). Single bolus administration of t-PA showed equivalent efficacy to infusion dosing for 60-minute infarct related vessel patency (88% vs 88%), microvascular reperfusion, and reocclusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: